GET THE APP

Mechanisms of Heavy Metal Neurotoxicity: Lead and Manganese
Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609

+44-20-4587-4809

Special Issue Article - (2016) Volume 7, Issue 1

Mechanisms of Heavy Metal Neurotoxicity: Lead and Manganese

April P. Neal1 and Tomás R. Guilarte2*
1Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
2Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, 722 West 168th Street, Room 1105-E, New York, NY 10032, USA
*Corresponding Author: Tomás R. Guilarte, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, 722 West 168th Street, Room 1105-E, New York, NY 10032, USA, Tel: 212-305-3959, Fax: 212-305-3857 Email:

Abstract

Human exposure to heavy metals is a global public health problem. Heavy metals which cause neurological toxicity, such as lead (Pb2+) and manganese (Mn), are of particular concern due to the long-lasting and possibly irreversible nature of their effects. Pb2+ exposure in childhood can result in cognitive and behavioral deficits in children. These effects are long-lasting and persist into adulthood even after Pb2+ exposure has been reduced or eliminated. While Mn is an essential element of the human diet and serves many cellular functions in the human body, elevated Mn levels can result in a Parkinson’s disease (PD)-like syndrome and developmental Mn exposure can adversely affect childhood neurological development. Due to the ubiquitous presence of both metals, reducing human exposure to toxic levels of Mn and Pb2+ remains a world-wide public health challenge. In this review we summarize the toxicokinetics of Pb2+ and Mn, describe their neurotoxic mechanisms, and discuss common themes in heavy metal toxicology.

Keywords: Lead; Manganese; Presynaptic; Neurotoxicity; Development; Brain

Introduction

It has been estimated that 1 billion people in the world suffer from some form of disability [1]. Of the top 20 health conditions resulting in disability, one quarter are neurological [1]. Furthermore, it has recently been estimated that the global prevalence of intellectual disability may be as high as 1% [2]. Additionally, mental disability prevalence rates were twice as high in developing countries as found in developed countries. Environmental factors, such as maternal and child health care, immunizations, and environmental pollution, can influence the prevalence of mental disability [2]. Thus, poorer health quality and higher contamination levels of pollutants in developing countries may contribute to the higher prevalence rates.

A prime agent implicated in cognitive and neurological deficits is environmental exposure to heavy metals. Heavy metal exposure can occur through contaminated air, food, water, or in hazardous occupations. While the levels of heavy metal contamination of the environment have decreased in recent decades in the developed world, the developing world experiences high levels of metal pollution. In particular, Asian and African countries have high levels of metal contamination, especially in urban environments [3,4]. This contamination largely derives from anthropogenic sources, such as the combustion of leaded gasoline or unregulated industrial emissions. There is also a significant problem with metal contamination from mining in developing countries, which results in elevated metal levels in water and air [5,6]. Another major source of metal contamination in developing countries is the practice of electronic waste recycling. Electronic waste, which is composed of used or broken computers, mobile phones, and other electronic devices contains valuable metals such as copper and gold. This waste is exported from developed countries for disposal in developing countries, where few regulations are in place regarding safe disposal [7]. Unfortunately, primitive and unsafe methods are used for the extraction of the precious metals, resulting in contamination of the local environment of highly toxic metals such as mercury and lead [8,9]. Due to the toxic nature of many of the chemicals and metals found in electronic waste, this pollution may have lasting detrimental effects on the neurodevelopment of children [10].

The heavy metals lead (Pb2+) and manganese (Mn) have both been shown to induce cognitive and behavioral deficits in adults and children with elevated levels of exposure [11-14]. While both metals can result in distinct neurological effects, with different brain targets and modes of action, they share a key similarity in that they both disrupt presynaptic neurotransmission. The aims of this review are to summarize the toxicokinetics of Pb2+ and Mn, describe their neurotoxic mechanisms, and discuss common themes in heavy metal toxicology.

Lead (Pb2+)

Pb2+ exposure has received world-wide attention due to its ability to cause behavioral and cognitive deficits in exposed children. The doseresponse of Pb2+ effects on the intelligence quotient (IQ) of children is non-linear, with lower exposures of Pb2+ resulting in a greater rate of IQ loss than at higher exposures [13,15,16]. These studies indicate that the majority of the estimated IQ loss in Pb2+-exposed children occurs during the first 10 μg/dL of exposure, and suggest that Pb2+ may be a non-threshold neurotoxicant [13,15,16]. Due to these effects, there have been global initiatives to reduce the use of Pb2+, but despite these efforts Pb2+ exposure remains a widespread problem [17,18].

Pb2+ Exposure

In the United States, Pb2+ was once commonly added to petrolbased fuel as an antiknock agent to improve engine efficiency. However, major concerns regarding Pb2+ exposure and its adverse effect on child neurological function [19,20] ultimately resulted in the reduction and eventual ban of leaded fuel. Analysis of population blood lead levels (BLLs) show that as Pb2+ was removed from gasoline, BLLs dropped significantly [21-24]. In a meta-analysis of 17 studies from 5 continents, the average BLL after removal of Pb2+ from gasoline was estimated to be 3 μg/dL [25]. This value is close to the current US population average BLL [26] and levels estimated in isolated populations [27], and may indicate background Pb2+ exposure from sources other than emissions from combustion of leaded gasoline. Alternative airborne sources of Pb2+ exposure include primary and secondary smelters and pistonengine aircraft, which still use Pb2+-containing gasoline [28].

As a result of evidence that Pb2+ in paint could cause neurological deficits when ingested by children, Pb2+ was removed from paint in Europe in 1922 and in the United States in 1978 [29,30]. However, banning the sale of leaded paint did not remove the threat of Pb2+ contamination in homes already containing leaded paint. Many homes in the United States still contain leaded paint [30,31], especially in city centers [32]. Chipped and peeling leaded paint constitutes a major source of current childhood Pb2+ exposure, as the desiccated paint can easily disintegrate at friction surfaces to form Pb2+ dust [33,34]. Pb2+ dust can also be formed from the combustion of leaded fuels; previous emissions of leaded fuel resulted in a massive dispersion of Pb2+ dust in the environment, especially along roadways [35]. Particulate Pb2+ is characteristically fine (2-10 μM) [35], does not degrade, and continues to be a major source of human exposure [32,36].

Drinking water can be another source of environmental Pb2+ exposure. Leaching of Pb2+ into drinking water occurs from outdated fixtures and solders containing Pb2+. The significance of Pb2+ leaching into drinking water was emphasized during the 2001 Washington, DC, “Lead in drinking water crisis”, when leaching of Pb2+ from pipes into drinking water rapidly increased the amount of Pb2+ contamination, resulting in a 9.6 fold increase in the incidence of elevated blood Pb2+ levels in children [37]. This unfortunate incident highlights the role contaminated drinking water can play in overall childhood Pb2+ exposure.

Due to the success of environmental interventions regarding Pb2+, childhood Pb2+ exposure in the US has decreased since the 1970’s. The most recent evidence indicates that contemporary childhood BLLs in the US are on the order of 1.9 μg/dL while the percentage of children with elevated BLLs (above 10 μg/dL) has dropped to 1.4% [26]. Peak BLLs occur when children are roughly 2 years of age [13,16,38,39]. Significant decreases in BLLs have been observed in this age group as well: average BLLs have decreased to 2.1 μg/dL and the percentage of children in this age group with elevated BLLs dropped to 2.4% [26]. Thus, the contemporary exposure levels for children in the US are generally under 3 μg/dL, and are approaching the levels of Pb2+ exposure measured in geographically isolated populations [27]. However, while the average BLLs in the US have decreased, there are still at-risk populations with higher than average BLLs. Children of lower social economic status (SES) or racial minority status are still at higher risk of Pb2+ poisoning [26] and some regions in the US have higher prevalence rates of elevated BLLs in children [40].

Pb2+ Toxicokinetics

The main routes of exposure for Pb2+ are inhalation and ingestion. Inhalation exposure to Pb2+ is a much more efficient route of absorption than ingestion, with an estimated absorption efficiency ratio of 10 to 1 in the lung compared to the GI tract [41,42]. Due to the reduction in use of leaded gasoline, inhalation exposure in developed countries is generally limited to people who live near smelters and to workers in occupational settings [43,44]. The deposition of inhaled inorganic Pb2+ is dependent on particle size and composition. Larger particles (> 2.5 μm) are deposited in the upper airways and can be cleared via mucociliary clearance. Particles < 1 μm penetrate to alveoli and are subsequently absorbed by phagocytosis. Particles cleared by mucociliary clearance can be subsequently ingested, contributing to Pb2+ exposure via ingestion [45].

Absorption of Pb2+ from the intestine is mediated by both passive and facilitated diffusion, although passive diffusion plays a minor role in total absorption [46]. Studies on the intestinal absorption of Pb2+ have consistently reported evidence of carrier-mediated transport [47,48], but the identity of the transporter or transporters is still a matter of debate. Some evidence supports the hypothesis that divalent metal transporter 1 (DMT1) is responsible for transporting Pb2+. DMT1 is a metal ion transporter that can transport metals such as Pb2+, Cd2+, and Zn2+ in addition to its physiological substrate, iron (Fe) [49]. Over expression of DMT1 in an intestinal cell culture model (CaCo-2) resulted in increased Pb2+ transport, but knockdown of the transporter did not abolish Pb2+ transfer [49]. Furthermore, a recent study established that Pb2+ is absorbed both in the duodenum, which exhibits high levels of DMT1, as well as the ileum which exhibits low expression of DMT1 [50,51]. Thus, while DMT1 likely plays a role in Pb2+ uptake from the GI tract, it is apparent that other carrier proteins exist. One such candidate is the calcium (Ca2+) binding protein calbindin, which is responsible for basolateral Ca2+ transfer in enterocytes and has been shown to bind both Pb2+ and Ca2+ with similar affinity (5 μM) [52,53]. Although never shown experimentally, hypothetically calbindin may basolaterally transport Pb2+ as well as Ca2+.

In blood, Pb2+ is primarily bound to protein. Up to 40% of blood Pb2+ (BPb) is bound to serum albumin, and the remaining BPb is bound to sulfhydryl- or thiol-containing ligands [54]. Work with the radiotracer 203-Pb in rats demonstrated that Pb2+ is taken up into the brain most likely as a free ion (PbOH+) or complexed with small molecular weight ligands. PbOH+ most likely crosses the blood brain barrier (BBB) through passive diffusion [55,56], but could also be transported through cation transporters [55]. DMT1 is highly expressed in the striatum, cortex, hippocampus, and cerebellum [57] and may facilitate Pb2+ transfer across the BBB [58]. Brain efflux is likely mediated through ATP-dependent Ca2+ pumps [56,59]. Within the brain, there is substantial debate regarding Pb2+ distribution; some studies have reported that Pb2+ preferentially accumulates in specific brain regions, such as the hippocampus [60]. However, other studies using different methodologies did not observe any differences in regional brain accumulation of Pb2+ [61].

About 94% of the human Pb2+ body burden is found in bone in adults, but only 73% in children. Pb2+ readily displaces Ca2+ in the bone matrix by cation-exchanges processes [62]. Recycling of Pb2+ between bone and blood occurs continuously; if recycling between blood and bone compartments could be eliminated the half-life of Pb2+ in blood would drop from 40 days to about 10 days [63]. Metabolic balance studies indicate Pb2+ is predominately excreted through feces, with urinary excretion playing a secondary role. Trace amounts of Pb2+ can also be excreted through hair, sweat, breast milk, and nails [64-66].

Child Susceptibility to Pb2+

Children are more susceptible to the effects of Pb2+ than adults for a number of reasons. First, children with hand to mouth behavior are at particular risk of elevated Pb2+ exposure due to the ingestion of Pb2+ dust [30]. Additionally, the BBB is immature during fetal development [67], which may contribute to greater accumulation of Pb2+ in the developing brain. Another factor is that children have a higher basal uptake of Pb2+ than adults. Adult human absorption of Pb2+ is around 10% [68] while infant absorption of Pb2+ is about 26.2% [66]. Radiolabel studies using 210Pb in rhesus monkeys demonstrated that young monkeys cleared less Pb2+, absorbed more Pb2+, and may have increased Pb2+ absorption from blood to soft tissues relative to adult animals [64]. In particular, the brains of young animals absorbed eight times the amount of Pb2+ compared to adult animals [69].

Partly due to increased absorption, children have a higher burden of mobile Pb2+ stores. As discussed above, children store less Pb2+ in bone, resulting in a higher BPb burdun. Furthermore, bone turnover in children due to skeletal growth results in a constant leaching of Pb2+ into the blood stream, causing continuous endogenous exposure [70]. Infants with low Pb2+ exposure actually have a higher excretion rate of Pb2+ than is accounted for by dietary intake, suggesting that Pb2+ stored in bone during fetal development and then mobilized by skeletal growth may contribute to a source of postnatal exposure [66,71].

Modifying factors in human Pb2+ exposure

Dietary factors can significantly impact Pb2+ absorption. Children deficient in Fe or Ca2+ are more likely to have elevated BLLs [72-75]. Supporting this observation, Fe-deficient animals retained five times the administered Pb2+ than animals with normal Fe levels [76]. One plausible mechanism for Fe-induced dietary alterations in Pb2+ absorption is through regulation of DMT1. DMT1 is regulated at the mRNA level by Fe through the iron response element [77], thus, iron-deficient diets increase the levels of DMT1 and concomitantly increase Pb2+ absorption [52,78]. Furthermore, DMT1 is found in brain endothelial cells of the BBB, so upregulation of DMT1 by Fe deficiency may also increase transport into the brain.

Neurotoxic effects of Pb2+: Results from Epidemiological Studies

The neurological effects of Pb2+ in exposed children have been a driving factor in reducing the level of Pb2+ in the environment. In 1991 the United States Centers for Disease Control and Prevention (CDC) lowered the definition of Pb2+ intoxication to 10 μg/dL BLL (the current regulatory level) motivated by the evidence from several studies that children with BLL of at least 10 μg/dL had impaired intellectual function [79]. More recently, studies have shown that the dose-response of Pb2+ on IQ in children is non-linear, with lower exposures of Pb2+ resulting in a greater rate of IQ loss than at higher exposures [13,15,16,80]. These data clearly demonstrate that the majority of the estimated IQ loss in Pb2+-exposed children occurs during the first 10 μg/dL, and many studies have suggested a lack of a threshold for the effects of Pb2+ on IQ [13,15,16].

A large, internationally-pooled analysis of Pb2+-exposed children estimated that children with BLLs of 10 μg/dL experience a deficit of about 6.2 IQ points relative to children with estimated BLLs of 1 μg/ dL [13]. This is comparable to the deficit of 7.4 IQ points observed in children with BLLs of 10 μg/dL in another large study [16]. On an individual level, a decrease in IQ of 6-7 points would be difficult to detect. However, the effect of a population decrease in IQ of this magnitude is quite significant. By shifting the normal distribution of IQ scores lower, the number of children with impaired intelligence would increase significantly while the number of exceptionally gifted children would decrease [29]. Several researchers have studied this effect from an economical standpoint and suggest that the monetary cost of such an effect may total over 40 billion dollars for one age group alone. Over a 20-year period, one generation, this loss may amount to nearly 800 billion dollars [29,81].

In addition to the cognitive deficits associated with Pb2+ exposure, children with elevated BLLs experience behavioral deficits. School children with elevated BLLs are more likely to act out in class, display antisocial behavior, and have trouble paying attention [82-84]. Cumulative childhood Pb2+ exposure was associated with a higher incidence in behavioral problems in 8-year-old children [83,85]. These behavioral effects appear to have a phenotype similar to attention deficit hyperactivity disorder (ADHD). Furthermore, recent studies have identified that childhood Pb2+ exposure is positivity associated with ADHD diagnosis [84,86].

The cognitive and behavioral deficits of Pb2+-exposed children persist even after the cessation of Pb2+ exposure [87], and chelation therapy is unable to remediate the effect of Pb2+ on cognition [88-90]. Prenatal and/or childhood Pb2+ exposure was associated with anti-social and delinquent behavior as adolescents [91], an increased likelihood be an adjudicated delinquent [92] or to be arrested as an adult [93]. Furthermore, childhood Pb2+ exposure may predict adult cognitive function [94]. Children who experience elevated Pb2+ levels are more likely to have decreased brain volume in adulthood in specific brain regions [95]. These changes could account for altered behavior and cognition in adults exposed to Pb2+ as children. Thus, developmental Pb2+ exposure in humans results in long-lasting effects on cognition and behavior even after cessation of exposure.

Possible Mechanism of Pb2+ Neurotoxicity: Results from experimental animal studies

It is believed that Pb2+ targets the learning and memory processes of the brain by inhibiting the N-methyl-D-aspartate receptor (NMDAR), which is essential for hippocampus-mediated learning and memory [96,97]. The NMDAR is essential for learning spatial navigation tasks in animal models [96], and animals which have been developmentally exposed to Pb2+ exhibit similar learning deficits as those with absent or impaired NMDARs [96-98].

The NMDAR is composed of an obligatory NR1 subunit and one or more accessory subunits from the NR2 and NR3 families. In the hippocampus, NR2A and NR2B are the most abundant NR2 family members. Pb2+ is a potent, non-competitive antagonist of the NMDAR [14,99-102]. Evidence suggests that Pb2+ binds the Zn2+ regulatory site of the NMDAR in a voltage-independent manner [103-105]. Since Zn2+ binds with high affinity at a regulatory site on the NR2A subunit [106], but with lower affinity to the NR2B subunit [107], this suggests a preferential sensitivity of NR2A-NMDARs for Pb2+ [103,105]. In support of this hypothesis, electrophysiological studies on recombinant receptors demonstrate that Pb2+ more potently inhibits NR2ANMDARs than NR2B-NMDARs [104,108] or the tri-heteromeric form, NR1/NR2A/NR2B-NMDAR [108].

In addition to acting as an NMDAR antagonist, Pb2+ exposure also disrupts normal NMDAR ontogeny. Chronic developmental Pb2+ exposure results in decreased NR2A content in the hippocampus [109-112] and altered expression of NR1 splice variants [112-114]. In contrast, NR2B mRNA levels either remained unchanged or slightly increased in rats developmentally exposed to Pb2+ [109-112,115]. Together, these data suggest that Pb2+ delays the normal developmental switch of increased NR2A incorporation in NMDARs with synapse maturation [14,115]. Similar trends have also been observed in cultured neuron systems [116,117] and suggest that Pb2+ exposure may cause lasting changes in NMDAR subunit composition and expression.

In addition to hippocampal changes in NMDAR subunit expression and ontogeny, Pb2+ may alter the cellular distribution of NMDAR populations. We have shown that Pb2+ exposure during synaptic development in hippocampal cultures reduces the levels of synaptic NR2A-NMDARs with a concomitant increase in extrasynaptic NR2B-NMDARs [116]. This is significant because the NR2 family members are linked to differential MAPK signaling [118], pro-death or pro-life signaling [119], and differential induction of nuclear gene expression [120]. In particular, NR2A-NMDAR activation is linked to cell survival pathways and cyclic AMP response element binding protein (CREB) activation while NR2B-NMDAR activation is linked to cell death pathways and CREB shutoff [120]. Thus, changes in synaptic localization of NMDARs by Pb2+ could alter downstream NMDAR-mediated signaling. Supporting this hypothesis, chronic developmental Pb2+ exposure results in altered MAPK signaling [121], calcium/calmodulin kinase II (CaMKII) activity [122], and altered CREB phosphorylation and binding affinity [115,123]. CREB is a transcription factor for many immediate early genes (IEGs), which play an essential role in memory consolidation and are expressed as a result of NMDAR activity [124]. Altered IEG expression in animals exposed to Pb2+ has been observed [125], indicating that altered CREB activity due to Pb2+-mediated disruption of NMDAR signaling may result in impaired learning and memory processes.

Pb2+ exposure can cause deficits in neurotransmission. Rats chronically exposed to low levels of Pb2+ have reduced Ca2+-dependent glutamate and γ-aminobutyric acid (GABA) release in the hippocampus [126-128], which indicates presynaptic neuron dysfunction during Pb2+ exposure. In cultured hippocampal neurons [129] and in brain slices [128], Pb2+ exposure impairs excitatory postsynaptic currents (EPSCs) and inhibitory postsynaptic currents (IPSCs). EPSCs and IPSCs are dependent upon neurotransmitter release from the presynaptic neuron, thus, reductions in EPSCs and IPSCs indicate a deficit in neurotransmission in both the glutamatergic and GABAergic systems as a result of Pb2+ exposure.

A recent study from our laboratory has shown that Pb2+ exposure in cultured hippocampal neurons during synaptic development resulted in altered presynaptic protein expression and deficits in vesicular neurotransmitter release [130]. Pb2+ exposure reduced the expression of key presynaptic proteins involved in vesicular release, such as synaptophysin (Syn) and synaptobrevin (Syb). Reductions of vesicular release proteins were associated with both glutamatergic and GABAergic synapses, consistent with electrophysiological observations regarding EPSC and IPSC generation during Pb2+ exposure [128,129]. Vesicular release in Pb2+-exposed neurons was significantly impaired relative to control conditions as determined by live-imaging studies using the synaptic vesicle dye FM 1-43 [130]. Together, animal and cell culture studies indicate a role for Pb2+ in presynaptic dysfunction which results in reduced neurotransmission [131].

One molecular mechanism by which Pb2+ may disrupt neurotransmission is by inhibiting neuronal voltage-gated calcium (Ca2+) channels (VGCCs) [132]. Removal of extracellular Ca2+ from hippocampal slice cultures resulted in identical effects on IPSC frequency as Pb2+ exposure, suggesting that the Pb2+-induced inhibition of IPSC frequency occurred via reduction of Ca2+ influx through VGCCs [128]. Inhibition of presynaptic VGCCs may prevent the necessary rise in internal Ca2+ required for fast, Ca2+-dependent vesicular release, thus interfering with neurotransmission. However, the effects of Pb2+ we observed on presynaptic protein expression were dependent on NMDAR activity, based on comparison studies with the specific NMDAR antagonist aminophosphonovaleric acid (APV, which does not inhibit VGCCs) which resulted in similar effects as Pb2+ exposure [130]. Thus, while Pb2+ inhibits VGCCs, which may result in impaired neurotransmission, VGCC inhibition by Pb2+ is not exclusively responsible for the presynaptic effects of Pb2+ and longterm NMDAR inhibition plays an important role in these effects.

An emerging theme in the mechanism of Pb2+ neurotoxicity is the disruption of intracellular Ca2+ dynamics. Inhibition of either VGCCs or NMDARs by Pb2+ would result in a significant reduction of Ca2+ entry into the cell. This is important because Ca2+ signaling is essential for synaptic development and plasticity [133,134] and perturbation of these processes can lead to neurological disease states [134,135]. One key Ca2+-dependent pathway involved in synaptic development and neurotransmitter release is brain-derived neurotrophic factor (BDNF) signaling [136-139]. BDNF is a trans-synaptic signaling molecule that is released from both axons and dendrites [139]. We have recently shown that BDNF levels are reduced in Pb2+-exposed cultures and that exogenous BDNF supplementation during Pb2+ exposure can fully mitigate the effects of Pb2+ on presynaptic function and protein expression [130]. Furthermore, BDNF expression and release are dependent on Ca2+ signaling, and both NMDAR- and VGCC-dependent Ca2+ pathways have been implicated in BDNF neurotransmission [139-141]. Interestingly, NMDAR-dependent release of BDNF may play a greater role in dendritic BDNF release rather than axonic BDNF [139]. This would support our hypothesis that NMDAR-dependent release of BDNF is disrupted during Pb2+ exposure [130,131], since the majority of NMDARs are postsynaptically located [142].

Regardless of whether Ca2+ disruption occurs via block of NMDAR or VGCC (or both), BDNF expression and release are impaired during Pb2+ exposure, which has effects on synaptic development [130] and may cause long-term impairment of hippocampal function in vivo. Interestingly in an animal study investigating the effects of environmental enrichment on Pb2+ exposure, animals exposed to Pb2+ but living in an enriched environment did not exhibit the deficits in spatial learning tasks usually observed in rats chronically exposed to Pb2+ [143]. In fact, Pb2+-exposed rats living in an enriched environment performed equally as rats which were not exposed to Pb2+. Furthermore, the Pb2+-exposed rats living in enriched environments exhibited elevated mRNA levels of BDNF relative to Pb2+-exposed rats living in normal conditions. This indicates that BDNF may be implicated in vivo in the effects of Pb2+ on learning and memory.

To summarize, Pb2+ remains a neurotoxiciant of concern due to its ubiquitious environmental presence and the absence of “safe” levels of exposure. Pb2+ exposure can cause both behavioral and cognitive deficits in children at very low (<10 μg/dL blood lead) levels of exposure. Recent progress has been made in the understanding of the cellular mechanism of Pb2+ toxicity, but further work is needed to address intervention and/or remediation strategies.

Manganese (Mn)

Manganese, an essential element of the human diet, is a naturally occurring component of the earth’s crust. After iron, Mn is the second most abundant heavy metal. Unlike Pb2+, which has no known physiological role, Mn has many beneficial roles in human physiology [144]. The adequate daily intake of Mn has been set by the National Academy of Sciences (NAS) at 2.3 mg/day for men and 1.8 mg/day for women [145]. Dietary Mn is sufficient to maintain adequate Mn homeostasis and Mn deficiencies in humans are exceedingly rare [144]. However, elevated Mn levels can cause human neurotoxicity. Notably, workers exposed to high airborne Mn levels are at elevated risk of developing a Parkinson’s disease (PD)-like neurological disorder known as manganism [146], and recently adverse effects of exposure to elevated Mn in drinking water have been observed in children [11,147- 149].

Mn Exposure and Toxicokinetics

While Mn can exist in 11 different oxidation states, Mn(II) and Mn(III) are the most biologically relevant [150-152]. The primary route for non-occupational exposures to Mn is ingestion. Three to five percent of ingested Mn is absorbed by the gut. Overt toxicity from ingestion is rare due to the tight regulation of Mn homeostasis coordinated through absorption and biliary excretion [144]. Biliary excretion is the predominate route of Mn excretion, but a fraction of Mn is reabsorbed in the gut, establishing an entero-hepatic loop [153]. Human Mn exposure can also occur through Mn contamination of drinking water and from Mn-containing agriculture agents, such as the fungicide Maneb [154]. There is significant concern regarding increased human exposure to Mn through use of the Mn-containing fuel additive methycyclopentadienyl manganese tricarbonyl (MMT) [155-157], and regions using MMT have elevated air Mn levels, particularly near roads with heavy traffic [158,159].

In contrast to the relatively minor routes of exposure listed above, exposure to airborne Mn in occupational settings is believed to be the cause of the majority of human Mn toxicity. In particular, miners, welders, smelters, workers of ferro-alloy plants, and drycell battery workers are at higher risk for Mn-related toxicity [160-165]. Airborne Mn is readily absorbed from the lung. As with Pb2+, pulmonary absorption of Mn is much higher than GI absorption [166] and pulmonary absorption of Mn likely occurs through Ca2+ channels [150,167]. Mn inhaled through the nose can access the olfactory bulb [168-170], which may be a direct route of Mn exposure to the brain.

The majority (80%) of Mn in blood (BMn) is bound to albumin, globulin, or transferrin [151]. A small fraction of BMn is present as Mn-citrate. From the blood, Mn crosses the blood brain barrier by facilitated diffusion or crosses cell membranes using DMT1-, Zrt-like/ Irt-like 8 (ZIP8), or transferrin-mediated mechanisms. Similar to Pb2+, Mn(II) may be transported by DMT1 both across the intestinal wall and across the BBB [170-172], although substantial debate exists regarding the contribution of DMT1 in brain Mn import [150]. Stronger evidence exists for transport of Mn into brain via transferrin (Tf). Mn(III) tightly binds Tf, forming a Mn-Tf complex [173]. Mn(II) may be oxidized to Mn(III) for subsequent loading onto Tf by ceruloplasmin (Cp), a protein which facilitates the oxidation of Fe(II) to Fe(III) [174]. However, recent evidence suggests that Cp does not oxidize Mn(II) and instead Mn(II) may either auto-oxidize in plasma or be oxidized by another pro-oxidant before binding Tf [175]. The Mn-Tf complex binds transferrin receptors (TfRs) and is subsequently endocytosed by brain microvascular endothelial cells. Within the endothelial cell, Mn dissociates from Tf by endosomal acidification and is transferred to the abluminal cell surface for release into the extracellular environment within the brain (for review, see [152]). While a role for Mn transport via ZIP8 has been proposed based on studies in cell culture models [152,176], physiological evidence of ZIP8 transport of Mn into the brain has yet to be established. There also may be a role for a storeoperated Ca2+ channel for Mn brain import [150]. Mn may also cross the choroid plexus into cerebrospinal fluid (CSF) and thus gain access to brain tissues, particularly at high BMn levels [177,178]. Once across the blood-brain or blood-CSF barriers, Mn is predominately found as Mn-citrate [151] and accumulates inside of neurons, oligodendrocytes, and astrocytes, likely via DMT-1 dependent mechanisms [152,172,179]. Brain efflux of Mn is likely mediated by diffusion [150]. Since several carrier-mediated import pathways exist while the only known efflux pathway is diffusion, Mn has the potential to be retained in the brain for an extended period.

Effects of Mn exposure in humans: Results from Epidemiological studies

Exposure to high levels of Mn can result in manganism, an extrapyramidal neurological disease characterized by rigidity, a mask-like expression, action tremor, bradykinesia, gait disturbances, memory and cognitive dysfunction, micrographia, and mood disorder [180-183]. The symptoms of manganism are strikingly similar to that of Parkinson’s disease (PD); however, manganism usually presents with marked differences from PD, such as insensitivity to levodopa (L-DOPA) administration and differences both in disease progression [12] and in symptoms [146]. While insensitivity to L-DOPA is generally considered a key difference between manganism and PD [12], some patients with manganism responded positively to L-DOPA therapy in a minority of studies [180,184,185]. However, it is possible that the cases which responded to L-DOPA may have had underlying PD etiology and that the effects of Mn are secondary to or compounded by those of PD [12].

The extra-pyramidal effects of Mn are thought to be mediated by Mn-induced neurotoxicity in the globus pallidus and other basal ganglia structures of the human brain [12,186]. The chemical characteristics of Mn lend an advantage to non-invasive measurement techniques; since Mn is a paramagnetic metal molecular imaging technique such as T1-weighted magnetic resonance imaging (T1-MRI), have allowed researchers to determine the distribution of Mn non-invasively in humans [12]. In humans occupationally exposed to airborne Mn, the metal accumulates in the basal ganglia [12,162]. Using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), it has been shown that elevated brain Mn can result in deficits in the dopaminergic system in exposed humans [12]. However, the results from studies on Mn-intoxicated humans need to be interpreted with care because several confounding factors, such as underlying PD, may influence the results.

Although the majority of our understanding of Mn neurotoxicity relates to adult exposures, there has been increasing evidence that Mn may have developmental neurotoxic effects in children. Recent epidemiological studies have shown that children who drink water from wells with elevated Mn levels exhibit both cognitive and behavioral deficits [11,147,148]. School children exhibited decreased IQ with increasing groundwater Mn exposure (Mn well water range 0.1-2700 μg/L, geometric mean=20 μg/L), with a decrease of 6.2 IQ points between the median of the lowest (1 μg/L) and highest (216 μg/L) Mn exposure quintiles [11]. Furthermore, school children who ingested well water with elevated Mn levels displayed more hyperactive behavior, aggressive behavior, and deficits in attention in school [147]. Children exposed to Mn from living in close proximity to a Mn alloy plant exhibited elevated hair Mn levels that were negatively associated with both full scale and verbal IQ scores [149]. In a longitudinal study of early-life Mn exposure examining neurodevelopment endpoints at 12 and 36 months of age, it was observed that high Mn exposure was negatively associated with neurodevelopment score [187]. Together these data suggest that excess exposure to Mn, like Pb2+, is a developmental neurotoxicant with both behavioral and cognitive effects in exposed children.

Susceptibility factors in Mn toxicity

Similar to Pb2+ exposure, children and infants are more susceptible to Mn poisoning than adults. Neonates in particular exhibit high Mn absorption rates, up to 40% of ingested Mn by some estimates [188], compared to roughly 3% absorption in adults [166]. Infants and especially neonates are further susceptible due to diminished biliary excretion [189], which is the major route of Mn excretion in humans [144]. An important source of exposure for this group is infant formula, particularly soy-based formula, which can contain 100 times the amount of Mn as human breast milk [144]. Children may be furthermore at risk for greater combined exposure from airborne Mn and ingested Mn based on physiology-based pharmacokinetics (PBPK) modeling incorporating the increased breathing rates, lower body masses, and increased GI absorption of children [190]. Based on this study, children may easily exceed the recommended dietary intake of Mn through a combination of airborne and dietary sources.

Deficits in biliary excretion as a result of liver injury or disease can also result in elevated Mn levels in blood [191] and in the basal ganglia [184,192,193]. Patients with elevated BMn due to liver disease exhibit motor deficits consistent with manganism, such as tremor, rigidity, and gait disturbances [184,194]. One postmortem study observed that patients with liver failure who exhibited parkinsonian symptoms had 4.7 fold higher brain Mn levels compared to patients with liver failure that had normal brain function [193]. If patients with compromised liver function receive a liver transplant, BMn levels decrease and in rare cases the neurological symptoms are reversed or lessened [195,196].

Similar to Pb2+ toxicity, dietary factors can influence Mn toxicity. Fe-deficient individuals exhibit higher Mn absorption likely due to upregulated DMT1 in the gut and in cells of the BBB [170,172]. Upregulation of DMT1 in the olfactory bulb due to iron deficiency has also been shown to increase Mn accumulation of Mn in the basal ganglia of rats [170].

Finally, patients receiving parenteral nutrition (PN) can experience elevated Mn levels [197,182], sometimes accompanied by parkinsonian movement disorders [198,199]. The elevated Mn levels are likely due to the fact that PN solutions without Mn supplementation still contain 7.3 μg/L of Mn as a contaminant [200]. Further Mn supplementation of PN solutions can result in an added 5.0-7.5 μg/kg body weight of Mn [144]. Under normal conditions only a fraction of ingested Mn is absorbed, but since PN bypasses the GI system patients who receive PN are likely to develop elevated BMn levels. Mn accumulation in the brain of patients on PN can be detected before clinical symptoms present [201], and if PN is removed Mn is cleared from the brain and BMn levels diminish [198,201].

Possible Mechanism of Mn Neurotoxicity: Results from laboratory studies

Within the substantia nigra (SN), globus pallidus (GP), and striatum (STR), Mn accumulates in neurons, astrocytes, and oligodendrocytes [152,172]. Intracellular Mn accumulates within the mitochondria, where it disrupts ATP synthesis [202]. The Ca2+ uniporter sequesters Mn in the mitochrondria, however, no known mitochondria export process exists, resulting in rapid Mn accumulation [203]. Until recently it was believed that Mn disrupted ATP synthesis by inhibiting the F1/ F0 ATP synthase [202] or complex 1 (NADH dehydrogenase) of the mitochondrial respiration chain [204]. However, a recent study revealed that Mn inhibits ATP synthesis at two sites in brain mitochondria, either complex II (succinate dehydrogenase) or the glutamate/aspartate exchanger, depending on the mitochondrial energy source [205]. Disruption of ATP synthesis leads to decreased intracellular ATP levels and increased oxidative stress [206,207], which may contribute to Mn cellular toxicity [208]. Further contributing to intracellular oxidative stress is the ability of Mn to oxidize dopamine (DA) to reactive quinone species (for review, see [209]). Between increased free radical generation via disrupted mitochondrial respiration and the oxidation of DA to reactive species, Mn exposure results in a decrease in the levels of free thiol and hydroxyl groups in cellular antioxidant proteins [209]. The increase in oxidative species combined with a decreased reductive capacity can result in dendritic degeneration [206] and cytotoxicity in culture systems [210].

The sensitivity of the dopaminergic system to Mn is an active area of investigation. Studies in nematode [211], cell culture [212], rodent [177,213,214], and non-human primate [215] models of Mn toxicity all demonstrate specific deficits in the dopaminergic system caused by Mn exposure. In contrast, the glutamatergic and GABA-ergic systems of the brain remain relatively unaffected by Mn exposure [216], and Mn(II) is more toxic to DA-producing cells than non-DA producing cells in vitro [212]. A recent study in C. elegans suggests that extracellular, not intracellular, DA is converted to the reactive species. This reactive DA species is taken up by the dopamine transporter (DAT1), thus resulting in dopaminergic neurotoxicity [211]. The findings of this study need to be confirmed in other model systems, but may indicate a basis for the enhanced sensitivity of the dopaminergic system to Mn(II).

Interestingly, the different species of Mn have different potencies in the cellular effects described above. Mn(III) is taken up by cells more efficiently than Mn(II) [217,218]. Furthermore, Mn(III) has a higher reduction potential than Mn(II), is a more potent oxidizer of DA than Mn(II), and is more cytotoxic than Mn(II) [217-220]. However, no difference was observed in the disruption of ATP synthesis between studies using Mn(II) or Mn(III) compounds [218]. The in vivo effects of Mn(II) and Mn(III) were compared in a rat study [221]. Adult female Sprague Dawley rats were injected intraperitoneally with either Mn(II)-chloride or Mn(III)-pyrophosphate and the effect of Mn species on brain Mn accumulation and effects were examined. Even with comparable BMn levels, Mn(III) exhibited greater accumulation in the brain, suggesting that either the uptake of Mn into the brain or retention of Mn in the brain may be dependent on oxidation state [221]. However, these differences could also be explained by the difference in solubility between Mn(II)-chloride or Mn(III)-pyrophosphate because Mn(III)-pyrophosphate has low solubility in biological media. Furthermore, this study did not observe regional differences in brain Mn accumulation, unlike studies in non-human primates [215] and Mn levels observed in occupationally-exposed humans [12] which demonstrate a clear tendency of Mn to accumulate in basal ganglia structures. This highlights the challenges in finding appropriate disease models of Mn. Studies in rodents are limited by the fact that rodents are less sensitive to Mn than are humans or non-human primates [12,222]. Rodents do not accumulate Mn in the same brain regions as humans or non-human primates [223]. Furthermore, rodent models of Mn toxicity do not develop analogous behavioral deficits as observed in humans or non-human primates chronically exposed to Mn [12].

For reasons described above, non-human primates remain the most relevant animal model of Mn intoxication for the human condition. In non-human primates, in vivo imaging studies have found that Mn accumulates preferentially in the caudate-putamen (CP), SN, and GP [215]. These findings have been supported in studies showing increased Mn content in the STR, GP, and SN of non-human primates using graphite furnace atomic absorption spectroscopy [177] and highresolution inductively-coupled plasma mass spectrometry (ICPMS) [224]. In the largest study of non-human primates chronically exposed to Mn, it was observed that DAT and dopamine receptor levels were unchanged in STR of Mn-exposed animals relative to controls. However, Mn-exposed animals had an altered response to amphetamine, which is a DAT substrate [225]. That is, Mn exposure resulted in a marked impairment of in vivo dopamine release in the STR of Mn-exposed non-human primates [224,225]. Several other studies have indicated that Mn can interact with DAT, although the exact mechanism is unclear [226-228]. An altered response to DAT ligands caused by Mn may indicate presynaptic deficits in the nigrostriatal system [224,225], which may explain the intractability of Mn-exposed subjects with parkinsonism to L-DOPA treatment. If there is reduced DA availability at the synapse due to impaired DA release or altered reuptake, then supplementation with L-DOPA would be ineffective at alleviating the movement disorders associated with Mn toxicity. Furthermore, the fact that the glutamatergic and GABAergic systems of non-human primates chronically exposed to Mn are unaffected in the presence of behavioral deficits suggests that the behavioral effects of Mn in non-human primates are related to the changes in the dopaminergic system [215,216]. Thus, even though cell culture and animal model systems of Mn toxicity suggest that the DA system has a special sensitivity to Mn, in humans and non-human primates this may not mean that Mn exposure causes DA neuron degeneration (as occurs in PD) but instead results in DA neuron dysfunction [12]. In support of this hypothesis, it was recently observed that welders can be asymptomatic for manganism but still exhibit a small increase in the United Parkinsons Disease Rating Scale (UPDRS) and exhibit dysfunctional L-DOPA uptake in the caudate measured by PET. This indicates presynaptic nigrostriatal deficits can precede overt symptoms of Mn-induced movement abnormalities [229] and may be an early neurochemical marker of dopaminergic dysfunction. Importantly, the pattern of L-DOPA uptake measured by PET in the caudate and putamen of welders was completely opposite to the pattern observed in idiopathic Parkinson’s disease patients. That is, in welders there was a significant decrease of L-DOPA uptake in the caudate with no change in the putamen, while idiopathic PD changes exhibit a change in the putamen and not in the caudate. This PET data shows that the pattern of change between welders with a subtle but significant increase in the UPDRS is distinctly different from patients with idiopathic Parkinson’s disease.

The effects of Mn on behavior and cognitive abilities in children may be related to effects on the dopaminergic system during development. In rodents, exposure to Mn during early postnatal development resulted in behavioral deficits reminiscent of hyperactivity as well as impaired performance on cognitive tests [230]. These neurological deficits were accompanied by altered DAT and DA receptor levels in the prefrontal cortex, nucleus accumbens, and dorsal striatum [230]. In monkey infants fed soy-based formula with or without supplemental Mn (1000 μg/L), the Mn-exposed animals exhibited a reduced response to the DA receptor agonist apomorphine, altered social interactions, and poorer learning rates in cognitive assessments [231]. Mn exposure in developing organisms may have lasting changes in the brain; rats exposed to Mn only during the pre-weaning time period exhibited altered DA receptor levels, altered response to DA agonists, and increased astrocyte activation in adulthood, even though the levels of Mn in blood and brain decreased [214]. These findings, especially the reduced response to DA receptor agonists, are consistent with what was observed in adult non-human primates [224], and indicates that deficits in DA neurotransmission during early development may result in lasting behavioral and cognitive deficits.

Conclusions

We have reviewed the neurotoxicology of two common environmental neurotoxicants, Pb2+ and Mn. While Mn is an essential element of the human diet and has many beneficial uses in the human body, elevated Mn levels can result in a PD-like syndrome and developmental Mn exposure can adversely affect childhood neurological development. In contrast, Pb2+ has no known physiological function and all known effects of Pb2+ are detrimental to humans. Like Mn, Pb2+ exposure in childhood can result in cognitive and behavioral deficits in children. These effects are long lasting and persist into adulthood even after Pb2+ exposure has been reduced or eliminated.

It is important to emphasize that one of the common links between Pb2+ and Mn neurotoxicity is presynaptic dysfunction. Pb2+ appears to interfere with glutamatergic neurotransmission and may disrupt trans-synaptic signaling critical to synaptic development [126,127,130,131,232]. Mn appears to interfere with dopaminergic synaptic transmission, possibly by impairing presynaptic DA release [215,224,225,233]. The developmental effects of either metal on cognition and behavior in children may be linked to this common theme of toxicity. The developing brain is particularly sensitive to agents that disrupt synaptic activity [234-236], as synaptic development depends critically on feedback signaling between neurons [232,237]. Furthermore, presynaptic dysfunction has been identified in many neurological disorders and diseases, including dementia, autism, bipolar disorder, Down syndrome, and schizophrenia (for review, see [134]). Interestingly, Pb2+ and/or Mn exposure has been linked to schizophrenia, dementia, PD, autism, and hyperactivity disorders as potential risk factors for disease etiology [86,238-244]. It is possible that presynaptic dysfunction may account for many of the chronic effects of Pb2+ and/or Mn exposure and increase susceptibility for neurological diseases which exhibit environmental etiology.

A common susceptibility factor for both Pb2+ and Mn toxicity is Fe deficiency. Fe-deficient diets can result in increased heavy metal uptake through increased DMT1 levels [78], which results in elevated BPb and BMn. This is significant particularly in developing countries. Developing countries tend to have higher environmental levels of Pb2+ and Mn, resulting in higher human exposure levels. Developing countries also have much higher rates of Fe deficiency than developed countries [245]. The WHO has estimated that 1.3% of the global disability burden stems from Fe deficiency, and that 40% of the burden occurs in Asia and another 25% occurs in Africa [245]. These same regions experience elevated levels of heavy metal contamination [246], resulting in a potentially devastating combination for metal toxicity. Indeed, a recent study in Pakistan showed a significant, dosedependent correlation between mild and severe anemia and BPb in children [247]. Thus, children in the developing world are at particular risk of experiencing metal toxicity, due to combined dietary deficits and elevated metal exposure.

Generally humans are not exposed to a single heavy metal, but instead are exposed to heterogeneous metal mixtures. The effect of human exposure to mixtures of heavy metals is currently an active area of research. Some parts of the world, such as northern Mexico [248] and Bangladesh [249-251], exhibit extremely high levels of as in the water table. Furthermore, co-exposure to high levels of Pb2+ and Mn also occurs. A recent study observed that combined exposure to Mn and As in Bangladeshi children was significantly associated with poorer performance on cognitive tests, although an interaction between the two metals was not supported statistically [148]. While an interaction was not observed in the Bangladesh study, in a study of children in Mexico the combined exposure to Pb2+ and Mn resulted in greater effects on cognitive performance than Pb2+ exposure alone [252]. This suggests that exposure to multiple metals may result in greater developmental deficits than to single metals and emphasizes the need to understand the toxicology of complex mixtures.

In conclusion, widespread exposure to Pb2+ and Mn continue to cause neurological deficits and disease. Heavy metal pollution is a global public health challenge, with a disproportionate burden laid upon developing nations. The developing world, with increased heavy metal contamination and higher prevalence of dietary deficiencies, is at particular risk for metal toxicity. The irreversible nature of the effects of Pb2+ and Mn on neurodevelopment strongly supports environmental intervention in regions where children are exposed to these metals via polluted air or ground water.

Acknowledgement

This work was originally prepared in partial fulfillment for the doctoral degree requirements for APN. Current email contact information for APN is: april.neal@ fda.hhs.gov. Some of the studies described in this review were funded by NIEHS grant number ES006189 and ES010975 to TRG.

References

  1. WHO (2011) World report on disability 2011. http://www.who.int/disabilities/world_report/2011/en/index.html Accessed 8/30/2011
  2. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S (2011) Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 32: 419-436.
  3. Gong M, Wu L, Bi XY, Ren LM, Wang L, et al. (2010) Assessing heavy-metal contamination and sources by GIS-based approach and multivariate analysis of urban-rural topsoils in Wuhan, central China. Environ Geochem Health 32: 59-72.
  4. Luo XS, Yu S, Zhu YG, Li XD (2012) Trace metal contamination in urban soils of China. Sci Total Environ 421-422: 17-30.
  5. Bhuiyan MA, Parvez L, Islam MA, Dampare SB, Suzuki S (2010) Heavy metal pollution of coal mine-affected agricultural soils in the northern part of Bangladesh. J Hazard Mater 173: 384-392.
  6. Huang X, Sillanpää M, Gjessing ET, Peräniemi S, Vogt RD (2010) Environmental impact of mining activities on the surface water quality in Tibet: Gyama valley. Sci Total Environ 408: 4177-4184.
  7. LaDou J, Lovegrove S (2008) Export of electronics equipment waste. Int J Occup Environ Health 14: 1-10.
  8. Haefliger P, Mathieu-Nolf M, Lociciro S, Ndiaye C, Coly M, et al. (2009) Mass lead intoxication from informal used lead-acid battery recycling in dakar, senegal. Environ Health Perspect 117: 1535-1540.
  9. Robinson BH (2009) E-waste: an assessment of global production and environmental impacts. Sci Total Environ 408: 183-191.
  10. Chen A, Dietrich KN, Huo X, Ho SM (2011) Developmental neurotoxicants in e-waste: an emerging health concern. Environ Health Perspect 119: 431-438.
  11. Bouchard MF, Sauvé S, Barbeau B, Legrand M, Brodeur MÈ, et al. (2011) Intellectual impairment in school-age children exposed to manganese from drinking water. Environ Health Perspect 119: 138-143.
  12. Guilarte TR (2010) Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect 118: 1071-1080.
  13. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, et al. (2005) Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 113: 894-899.
  14. Toscano CD, Guilarte TR (2005) Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev 49: 529-554.
  15. Jusko TA, Henderson CR, Lanphear BP, Cory-Slechta DA, Parsons PJ, et al. (2008) Blood lead concentrations < 10 microg/dL and child intelligence at 6 years of age. Environ Health Perspect 116: 243-248.
  16. Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, et al. (2003) Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 348: 1517-1526.
  17. Meyer PA, Brown MJ, Falk H (2008) Global approach to reducing lead exposure and poisoning. Mutat Res 659: 166-175.
  18. Callan AC, Hinwood AL (2011) Exposures to lead. Rev Environ Health 26: 13-15.
  19. Needleman HL, Epstein S, Carnow B, Scanlon J, Parkinson D, et al. (1975) Letter: Blood-lead levels, behaviour and intelligence. Lancet 1: 751-752.
  20. Needleman HL, Scanlon J (1973) Getting the lead out. N Engl J Med 288: 466-467.
  21. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, et al. (1998) Exposure of the U.S. population to lead, 1991-1994. Environ Health Perspect 106: 745-750.
  22. Nichani V, Li WI, Smith MA, Noonan G, Kulkarni M, et al. (2006) Blood lead levels in children after phase-out of leaded gasoline in Bombay, India. Sci Total Environ 363: 95-106.
  23. Stromberg U, Lundh T, Skerfving S (2008) Yearly measurements of blood lead in Swedish children since 1978: The declining trend continues in the petrol-lead-free period 1995-2007. Env Res. 107: 332-335.
  24. Wang W, Liu X, Zhao L, Guo D, Tian X, et al. (2006) Effectiveness of leaded petrol phase-out in Tianjin, China based on the aerosol lead concentration and isotope abundance ratio. Sci Total Environ 364: 175-187.
  25. Thomas VM, Socolow RH, Fanelli JJ, Spiro TG (1999) Effects of reducing lead in gasoline: An analysis of the international experience. SciTotal Environ. 33: 3942-3948.
  26. Jones RL, Homa DM, Meyer PA, Brody DJ, Caldwell KL, et al. (2009) Trends in blood lead levels and blood lead testing among US children aged 1 to 5 years, 1988-2004. Pediatrics 123: e376-385.
  27. Piomelli S, Corash L, Corash MB, Seaman C, Mushak P, et al. (1980) Blood lead concentrations in a remote Himalayan population. Science 210: 1135-1137.
  28. US EPA (2008) Fact sheet: final revisions to the national ambient air quality standards for lead. http://www.epa.gov/air/lead/pdfs/20081015pbfactsheet.pdf Accessed 8/30/2011
  29. Gilbert SG, Weiss B (2006) A rationale for lowering the blood lead action level from 10 to 2 microg/dL. Neurotoxicology 27: 693-701.
  30. Gibson JL (2005) A plea for painted railings and painted walls of rooms as the source of lead poisoning amongst Queensland children. 1904. Public Health Rep 120: 301-304.
  31. Jacobs DE, Clickner RP, Zhou JY, Viet SM, Marker DA, et al. (2002) The prevalence of lead-based paint hazards in U.S. housing. Environ Health Perspect 110: A599-606.
  32. Gasana J, Chamorro A (2002) Environmental lead contamination in Miami inner-city area. J Expo Anal Environ Epidemiol 12: 265-272.
  33. Levin R, Brown MJ, Kashtock ME, Jacobs DE, Whelan EA, et al. (2008) Lead exposures in U.S. Children, 2008: implications for prevention. Environ Health Perspect 116: 1285-1293.
  34. Rabinowitz M, Leviton A, Bellinger D (1985) Home refinishing, lead paint, and infant blood lead levels. Am J Public Health 75: 403-404.
  35. Luo XS, Yu S, Li XD (2011) Distribution, availability, and sources of trace metals in different particle size fractions of urban soils in Hong Kong: Implications for assessing the risk to human health. Environ Pollut 159: 1317-1326.
  36. Mielke HW, Reagan PL (1998) Soil is an important pathway of human lead exposure. Environ Health Perspect 106 Suppl 1: 217-229.
  37. Edwards M, Triantafyllidou S, Best D (2009) Elevated blood lead in young children due to lead-contaminated drinking water: Washington, DC, 2001-2004. Environ Sci Technol 43: 1618-1623.
  38. Billick IH, Curran AS, Shier DR (1979) Analysis of pediatric blood lead levels in New York City for 1970-1976. Environ Health Perspect 31: 183-190.
  39. Hayes EB, McElvaine MD, Orbach HG, Fernandez AM, Lyne S, et al. (1994) Long-term trends in blood lead levels among children in Chicago: relationship to air lead levels. Pediatrics 93: 195-200.
  40. Scott LL, Nguyen LM (2011) Geographic region of residence and blood lead levels in US children: results of the National Health and Nutrition Examination Survey. Int Arch Occup Environ Health 84: 513-522.
  41. Hodgkins DG, Robins TG, Hinkamp DL, Schork MA, Levine SP, et al. (1991) The effect of airborne lead particle size on worker blood-lead levels: an empirical study of battery workers. J Occup Med 33: 1265-1273.
  42. Wells AC, Venn JB, Heard MJ (1975) Deposition in the lung and uptake to blood of motor exhaust labelled with 203Pb. Inhaled Part 4 Pt 1: 175-189.
  43. Hilts SR (2003) Effect of smelter emission reductions on children's blood lead levels. Sci Total Environ 303: 51-58.
  44. Rodrigues EG, Virji MA, McClean MD, Weinberg J, Woskie S, et al. (2010) Personal exposure, behavior, and work site conditions as determinants of blood lead among bridge painters. J Occup Environ Hyg 7: 80-87.
  45. US Department of Health and Human Services: Agency for Toxic Substances and Disease Registry, (2007) Toxicological Profile for Lead (Update).
  46. Aungst BJ, Fung HL (1981) Kinetic characterization of in vitro lead transport across the rat small intestine: mechanism of intestinal lead transport. Toxicol Appl Pharmacol 61: 39-47.
  47. Barton JC, Conrad, ME, Nuby S, Harrison L (1978) Effects of iron on the absorption and retention of lead. J Lab Clin Med. 92: 536-547.
  48. Fullmer CS (1990) Intestinal lead and calcium absorption: effect of 1,25-dihydroxycholecalciferol and lead status. Proc Soc Exp Biol Med. 194: 258-264.
  49. Bannon DI, Abounader R, Lees PS, Bressler JP (2003) Effect of DMT1 knockdown on iron, cadmium, and lead uptake in Caco-2 cells. Am J Physiol Cell Physiol 284: C44-50.
  50. Canonne-Hergaux F, Gruenheid S, Ponka P, Gros P (1999) Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 93: 4406-4417.
  51. Elsenhans B, Janser H, Windisch W, Schümann K (2011) Does lead use the intestinal absorptive pathways of iron? Impact of iron status on murine ²¹⁰Pb and ⁵⁹Fe absorption in duodenum and ileum in vivo. Toxicology 284: 7-11.
  52. Bressler JP, Olivi L, Cheong JH, Kim Y, Maerten A, et al. (2007) Metal transporters in intestine and brain: their involvement in metal-associated neurotoxicities. Hum Exp Toxicol 26: 221-229.
  53. Richardt G, Federolf G, Habermann E (1986) Affinity of heavy metal ions to intracellular Ca2+-binding proteins. Biochem Pharmacol 35: 1331-1335.
  54. Al-Modhefer AJ, Bradbury MW, Simons TJ (1991) Observations on the chemical nature of lead in human blood serum. Clin Sci (Lond) 81: 823-829.
  55. Bradbury MW, Deane R (1993) Permeability of the blood-brain barrier to lead. Neurotoxicology 14: 131-136.
  56. Yokel RA (2006) Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 10: 223-253.
  57. Williams K, Wilson MA, Bressler J (2000) Regulation and developmental expression of the divalent metal-ion transporter in the rat brain. Cell Mol Biol (Noisy-le-grand) 46: 563-571.
  58. Wang Q, Luo W, Zhang W, Liu M, Song H, et al. (2011) Involvement of DMT1 +IRE in the transport of lead in an in vitro BBB model. Toxicol In Vitro 25: 991-998.
  59. Marchetti C (2003) Molecular targets of lead in brain neurotoxicity. Neurotox Res 5: 221-236.
  60. Fjerdingstad EJ, Danscher G, Fjerdingstad E (1974) Hippocampus: selective concentration of lead in the normal rat brain. Brain Res 80: 350-354.
  61. Widzowski DV, Cory-Slechta DA (1994) Homogeneity of regional brain lead concentrations. Neurotoxicology 15: 295-307.
  62. Pounds JG, Long GJ, Rosen JF (1991) Cellular and molecular toxicity of lead in bone. Environ Health Perspect 91: 17-32.
  63. Brito JA, McNeill FE, Webber CE, Chettle DR (2005) Grid search: an innovative method for the estimation of the rates of lead exchange between body compartments. J Environ Monit 7: 241-247.
  64. Pounds JG, Marlar RJ, Allen JR (1978) Metabolism of lead-210 in juvenile and adult rhesus monkeys (Macaca mulatta). Bull Environ Contam Toxicol 19: 684-691.
  65. Rabinowitz M, Wetherill GW, Kopple JD (1974) Studies of human lead metabolism by use of stable isotope tracers. Environ Health Perspect 7: 145-153.
  66. Ziegler EE, Edwards BB, Jensen RL, Mahaffey KR, Fomon SJ (1978) Absorption and retention of lead by infants. Pediatr Res 12: 29-34.
  67. Johansson PA, Dziegielewska KM, Liddelow SA, Saunders NR (2008) The blood-CSF barrier explained: when development is not immaturity. Bioessays 30: 237-248.
  68. Hursh JB, Suomela J (1968) Absorption of 212Pb from the gastrointestinal tract of man. Acta Radiol Ther Phys Biol 7: 108-120.
  69. Kostial K, Kello D, Jugo S, Rabar I, Maljković T (1978) Influence of age on metal metabolism and toxicity. Environ Health Perspect 25: 81-86.
  70. Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ (2005) A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 113: 1669-1674.
  71. Gulson BL, Mizon KJ, Palmer JM, Patison N, Law AJ, et al. (2001) Longitudinal study of daily intake and excretion of lead in newly born infants. Environ Res 85: 232-245.
  72. Ballew C, Khan LK, Kaufmann R, Mokdad A, Miller DT, et al. (1999) Blood lead concentration and children's anthropometric dimensions in the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Pediatr 134: 623-630.
  73. Mahaffey KR, Annest JL (1986) Association of erythrocyte protoporphyrin with blood lead level and iron status in the second National Health and Nutrition Examination Survey, 1976-1980. Environ Res 41: 327-338.
  74. Mahaffey KR, Gartside PS, Glueck CJ (1986) Blood lead levels and dietary calcium intake in 1- to 11-year-old children: the Second National Health and Nutrition Examination Survey, 1976 to 1980. Pediatrics 78: 257-262.
  75. Marcus AH, Schwartz J (1987) Dose-response curves for erythrocyte protoporphyrin vs blood lead: effects of iron status. Environ Res 44: 221-227.
  76. Ragan HA (1977) Effects of iron deficiency on the absorption and distribution of lead and cadmium in rats. J Lab Clin Med 90: 700-706.
  77. Nemeth E (2008) Iron regulation and erythropoiesis. Curr Opin Hematol 15: 169-175.
  78. Yeh KY, Yeh M, Watkins JA, Rodriguez-Paris J, Glass J (2000) Dietary iron induces rapid changes in rat intestinal divalent metal transporter expression. Am J Physiol Gastrointest Liver Physiol 279: G1070-1079.
  79. Needleman HL, Gatsonis CA (1990) Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. JAMA 263: 673-678.
  80. Hu H, Téllez-Rojo MM, Bellinger D, Smith D, Ettinger AS, et al. (2006) Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. Environ Health Perspect 114: 1730-1735.
  81. Landrigan PJ, Schechter CB, Lipton JM, Fahs MC, Schwartz J (2002) Environmental pollutants and disease in American children: estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities. Environ Health Perspect 110: 721-728.
  82. Needleman HL, Riess JA, Tobin MJ, Biesecker GE, Greenhouse JB (1996) Bone lead levels and delinquent behavior. JAMA 275: 363-369.
  83. Bellinger D, Leviton A, Allred E, Rabinowitz M (1994) Pre- and postnatal lead exposure and behavior problems in school-aged children. Environ Res 66: 12-30.
  84. Roy A, Bellinger D, Hu H, Schwartz J, Ettinger AS, et al. (2009) Lead exposure and behavior among young children in Chennai, India. Environ Health Perspect 117: 1607-1611.
  85. Leviton A, Bellinger D, Allred EN, Rabinowitz M, Needleman H, et al. (1993) Pre- and postnatal low-level lead exposure and children's dysfunction in school. Environ Res 60: 30-43.
  86. Froehlich TE, Lanphear BP, Auinger P, Hornung R, Epstein JN, et al. (2009) Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder. Pediatrics 124: e1054-1063.
  87. White LD, Cory-Slechta DA, Gilbert ME, Tiffany-Castiglioni E, Zawia NH, et al. (2007) New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 225: 1-27.
  88. Chisolm JJ Jr (1990) Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures. Environ Health Perspect 89: 67-74.
  89. Dietrich KN, Ware JH, Salganik M, Radcliffe J, Rogan WJ, et al. (2004) Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 114: 19-26.
  90. Rogan WJ, Dietrich KN, Ware JH, Dockery DW, Salganik M, et al. (2001) The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 344: 1421-1426.
  91. Dietrich KN, Ris MD, Succop PA, Berger OG, Bornschein RL (2001) Early exposure to lead and juvenile delinquency. Neurotoxicol Teratol 23: 511-518.
  92. Needleman HL, McFarland C, Ness RB, Fienberg SE, Tobin MJ (2002) Bone lead levels in adjudicated delinquents. A case control study. Neurotoxicol Teratol 24: 711-717.
  93. Wright JP, Dietrich KN, Ris MD, Hornung RW, Wessel SD, et al. (2008) Association of prenatal and childhood blood lead concentrations with criminal arrests in early adulthood. PLoS Med 5: e101.
  94. Mazumdar M, Bellinger DC, Gregas M, Abanilla K, Bacic J, et al. (2011) Low-level environmental lead exposure in childhood and adult intellectual function: a follow-up study. Environ Health 10: 24.
  95. Cecil KM, Brubaker CJ, Adler CM, Dietrich KN, Altaye M et al. (2008) Decreased brain volume in adults with childhood lead exposure. PLoS Med 5: 0741-0749.
  96. Morris RG, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319: 774-776.
  97. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-683.
  98. Tsien JZ, Huerta PT, Tonegawa S (1996) The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87: 1327-1338.
  99. Alkondon M, Costa AC, Radhakrishnan V, Aronstam RS, Albuquerque EX (1990) Selective blockade of NMDA-activated channel currents may be implicated in learning deficits caused by lead. FEBS Lett 261: 124-130.
  100. Guilarte TR, Miceli RC (1992) Age-dependent effects of lead on [3H]MK-801 binding to the NMDA receptor-gated ionophore: in vitro and in vivo studies. Neurosci Lett 148: 27-30.
  101. Guilarte TR, Miceli RC, Jett DA (1994) Neurochemical aspects of hippocampal and cortical Pb2+ neurotoxicity. Neurotoxicology 15: 459-466.
  102. Ruan DY, Chen JT, Zhao C, Xu YZ, Wang M, et al. (1998) Impairment of long-term potentiation and paired-pulse facilitation in rat hippocampal dentate gyrus following developmental lead exposure in vivo. Brain Res 806: 196-201.
  103. Gavazzo P, Zanardi I, Baranowska-Bosiacka I, Marchetti C (2008) Molecular determinants of Pb2+ interaction with NMDA receptor channels. Neurochem Int 52: 329-337.
  104. Yamada Y, Ujihara H, Sada H, Ban T (1995) Pb2+ reduces the current from NMDA receptors expressed in Xenopus oocytes. FEBS Lett 377: 390-392.
  105. Guilarte TR, Miceli RC, Jett DA (1995) Biochemical evidence of an interaction of lead at the zinc allosteric sites of the NMDA receptor complex: effects of neuronal development. Neurotoxicology 16: 63-71.
  106. Fayyazuddin A, Villarroel A, Le Goff A, Lerma J, Neyton J (2000) Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors. Neuron 25: 685-694.
  107. Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P (2005) The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25: 308-317.
  108. Omelchenko IA, Nelson CS, Marino JL, Allen CN (1996) The sensitivity of N-methyl-D-aspartate receptors to lead inhibition is dependent on the receptor subunit composition. J Pharmacol Exp Ther 278: 15-20.
  109. Guilarte TR and McGlothan JL (1998) Hippocampal NMDA receptor mRNA undergoes subunit specific changes during developmental lead exposure. Brain Res. 790: 98-107.
  110. Nihei MK, Desmond NL, McGlothan JL, Kuhlmann AC, Guilarte TR (2000) N-methyl-D-aspartate receptor subunit changes are associated with lead-induced deficits of long-term potentiation and spatial learning. Neuroscience 99: 233-242.
  111. Nihei MK, Guilarte TR (1999) NMDAR-2A subunit protein expression is reduced in the hippocampus of rats exposed to Pb2+ during development. Brain Res Mol Brain Res 66: 42-49.
  112. Zhang XY, Liu AP, Ruan DY, Liu J (2002) Effect of developmental lead exposure on the expression of specific NMDA receptor subunit mRNAs in the hippocampus of neonatal rats by digoxigenin-labeled in situ hybridization histochemistry. Neurotoxicol Teratol 24: 149-160.
  113. Guilarte TR, McGlothan JL, Nihei MK (2000) Hippocampal expression of N-methyl-D-aspartate receptor (NMDAR1) subunit splice variant mRNA is altered by developmental exposure to Pb2+. Mol Brain Res. 76: 299-305.
  114. Guilarte TR, McGlothan JL (2003) Selective decrease in NR1 subunit splice variant mRNA in the hippocampus of Pb2+-exposed rats: implications for synaptic targeting and cell surface expression of NMDAR complexes. Brain Res Mol Brain Res 113: 37-43.
  115. Toscano CD, Hashemzadeh-Gargari H, McGlothan JL, Guilarte TR (2002) Developmental Pb2+ exposure alters NMDAR subtypes and reduces CREB phosphorylation in the rat brain. Brain Res Dev Brain Res 139: 217-226.
  116. Neal AP, Worley PF, Guilarte TR (2011) Lead exposure during synaptogenesis alters NMDA receptor targeting via NMDA receptor inhibition. Neurotoxicology 32: 281-289.
  117. Xu SZ, Rajanna B (2006) Glutamic acid reverses Pb2+-induced reductions of NMDA receptor subunits in vitro. Neurotoxicology 27: 169-175.
  118. Kim MJ, Dunah AW, Wang YT, Sheng M (2005) Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 46: 745-760.
  119. Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, et al. (2008) Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci 28: 10696-10710.
  120. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5: 405-414.
  121. Cordova FM, Rodrigues AL, Giacomelli MB, Oliveira CS, Posser T, et al. (2004) Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res 998: 65-72.
  122. Toscano CD, O'Callaghan JP, Guilarte TR (2005) Calcium/calmodulin-dependent protein kinase II activity and expression are altered in the hippocampus of Pb2+-exposed rats. Brain Res 1044: 51-58.
  123. Toscano CD, McGlothan JL, Guilarte TR (2003) Lead exposure alters cyclic-AMP response element binding protein phosphorylation and binding activity in the developing rat brain. Brain Res Dev Brain Res 145: 219-228.
  124. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, et al. (1994) Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 79: 59-68.
  125. Kim KA, Chakraborti T, Goldstein G, Johnston M, Bressler J (2002) Exposure to lead elevates induction of zif268 and Arc mRNA in rats after electroconvulsive shock: the involvement of protein kinase C. J Neurosci Res 69: 268-277.
  126. Lasley SM, Gilbert ME (1996) Presynaptic glutamatergic function in dentate gyrus in vivo is diminished by chronic exposure to inorganic lead. Brain Res 736: 125-134.
  127. Lasley SM, Gilbert ME (2002) Rat hippocampal glutamate and GABA release exhibit biphasic effects as a function of chronic lead exposure level. Toxicol Sci 66: 139-147.
  128. Xiao C, Gu Y, Zhou CY, Wang L, Zhang MM, et al. (2006) Pb2+ impairs GABAergic synaptic transmission in rat hippocampal slices: a possible involvement of presynaptic calcium channels. Brain Res 1088: 93-100.
  129. Braga MF, Pereira EF, Albuquerque EX (1999) Nanomolar concentrations of lead inhibit glutamatergic and GABAergic transmission in hippocampal neurons. Brain Res 826: 22-34.
  130. Neal AP, Stansfield KH, Worley PF, Thompson RE, Guilarte TR (2010) Lead exposure during synaptogenesis alters vesicular proteins and impairs vesicular release: potential role of NMDA receptor-dependent BDNF signaling. Toxicol Sci 116: 249-263.
  131. Neal AP, Guilarte TR (2010) Molecular neurobiology of lead (Pb(2+)): effects on synaptic function. Mol Neurobiol 42: 151-160.
  132. Peng S, Hajela RK, Atchison WD (2002) Characteristics of block by Pb2+ of function of human neuronal L-, N-, and R-type Ca2+ channels transiently expressed in human embryonic kidney 293 cells. Mol Pharmacol 62: 1418-1430.
  133. Konur S, Ghosh A (2005) Calcium signaling and the control of dendritic development. Neuron 46: 401-405.
  134. Waites CL, Garner CC (2011) Presynaptic function in health and disease. Trends Neurosci 34: 326-337.
  135. Mirnics K, Middleton FA, Lewis DA, Levitt P (2001) Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24: 479-486.
  136. Chen WG, Chang Q, Lin Y, Meissner A, West AE, et al. (2003) Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302: 885-889.
  137. Shieh PB, Ghosh A (1999) Molecular mechanisms underlying activity-dependent regulation of BDNF expression. J Neurobiol 41: 127-134.
  138. Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20: 727-740.
  139. Matsuda N, Lu H, Fukata Y, Noritake J, Gao H, et al. (2009) Differential activity-dependent secretion of brain-derived neurotrophic factor from axon and dendrite. J Neurosci 29: 14185-14198.
  140. Jiang X, Tian F, Mearow K, Okagaki P, Lipsky RH, et al. (2005) The excitoprotective effect of N-methyl-D-aspartate receptors is mediated by a brain-derived neurotrophic factor autocrine loop in cultured hippocampal neurons. J Neurochem 94: 713-722.
  141. Walz C, Jüngling K, Lessmann V, Gottmann K (2006) Presynaptic plasticity in an immature neocortical network requires NMDA receptor activation and BDNF release. J Neurophysiol 96: 3512-3516.
  142. Wenthold RJ, Prybylowski K, Standley S, Sans N, Petralia RS (2003) Trafficking of NMDA receptors. Annu Rev Pharmacol Toxicol 43: 335-358.
  143. Guilarte TR, Toscano, CD, McGlothan JL, Weaver SA (2003) Environmental enrichment reverses cognitive and molecular deficits induced by developmental lead exposure. Ann Neurol. 53: 50-56.
  144. Aschner JL, Aschner M (2005) Nutritional aspects of manganese homeostasis. Mol Aspects Med 26: 353-362.
  145. Trumbo P, Yates AA, Schlicker S, Poos M (2001) Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 101: 294-301.
  146. Cersosimo MG and Koller WC (2006) The diagnosis of manganese-induced parkinsonism. Neurotoxicology. 27: 340-346.
  147. Khan K, Factor-Litvak P, Wasserman GA, Liu X, Ahmed E et al. (2011) Manganese exposure from drinking water and children's classroom behavior in Bangladesh. Environ Health Perspect. Online 14 April 2011
  148. Wasserman GA, Liu X, Parvez F, Factor-Litvak P, Ahsan H, et al. (2011) Arsenic and manganese exposure and children's intellectual function. Neurotoxicology 32: 450-457.
  149. Menezes-Filho JA, Novaes Cde O, Moreira JC, Sarcinelli PN, Mergler D (2011) Elevated manganese and cognitive performance in school-aged children and their mothers. Environ Res 111: 156-163.
  150. Yokel RA (2009) Manganese flux across the blood-brain barrier. Neuromolecular Med 11: 297-310.
  151. Michalke B, Berthele A, Mistriotis P, Ochsenkuhn-Petropoulou M, Halbach S (2007) Manganese species from human serum, cerebrospinal fluid analyzed by size exclusion chromatography-, capillary electrophoresis coupled to inductively coupled plasma mass spectrometry. J Trace Elem Med Biol. 21 Suppl 1: 4-9.
  152. Aschner M, Guilarte TR, Schneider JS, Zheng W (2007) Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 221: 131-147.
  153. Schroeder HA, Balassa JJ, Tipton IH (1966) Essential trace metals in man: manganese. A study in homeostasis. J Chronic Dis 19: 545-571.
  154. Ferraz HB, Bertolucci PH, Pereira JS, Lima JG, Andrade LA (1988) Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 38: 550-553.
  155. Walsh MP (2007) The global experience with lead in gasoline and the lessons we should apply to the use of MMT. Am J Ind Med 50: 853-860.
  156. Davis JM (1999) Inhalation health risks of manganese: an EPA perspective. Neurotoxicology 20: 511-518.
  157. Zayed J, Vyskocil A, Kennedy G (1999) Environmental contamination and human exposure to manganese--contribution of methylcyclopentadienyl manganese tricarbonyl in unleaded gasoline. Int Arch Occup Environ Health 72: 7-13.
  158. Bankovitch V, Carrier G, Gagnon C, Normandin L, Kennedy G, et al. (2003) Total suspended particulate manganese in ambient air in Montreal 1981-2000. Sci Total Environ 308: 185-193.
  159. Boudia N, Halley R, Kennedy G, Lambert J, Gareau L et al.(2006) Manganese concentrations in the air of the Montreal (Canada) subway in relation to surface automobile traffic density. Sci Total Environ. 366: 143-147.
  160. Lucchini R, Apostoli P, Perrone C, Placidi D, Albini E, et al. (1999) Long-term exposure to "low levels" of manganese oxides and neurofunctional changes in ferroalloy workers. Neurotoxicology 20: 287-297.
  161. Chandra SV, Shukla GS, Srivastava RS, Singh H, Gupta VP (1981) An exploratory study of manganese exposure to welders. Clin Toxicol 18: 407-416.
  162. da Silva CJ, da Rocha AJ, Mendes MF, Braga AP, Jeronymo S (2008) Brain manganese deposition depicted by magnetic resonance imaging in a welder. Arch Neurol 65: 983.
  163. Wang JD, Huang CC, Hwang YH, Chiang JR, Lin JM, et al. (1989) Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br J Ind Med 46: 856-859.
  164. Roels HA, Ortega Eslava MI, Ceulemans E, Robert A, Lison D (1999) Prospective study on the reversibility of neurobehavioral effects in workers exposed to manganese dioxide. Neurotoxicology 20: 255-271.
  165. Roels HA, Ghyselen P, Buchet JP, Ceulemans E, Lauwerys RR (1992) Assessment of the permissible exposure level to manganese in workers exposed to manganese dioxide dust. Br J Ind Med 49: 25-34.
  166. Andersen ME, Gearhart JM, Clewell HJ 3rd (1999) Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. Neurotoxicology 20: 161-171.
  167. Heilig EA, Thompson KJ, Molina RM, Ivanov AR, Brain JD, et al. (2006) Manganese and iron transport across pulmonary epithelium. Am J Physiol Lung Cell Mol Physiol 290: L1247-1259.
  168. Brenneman KA, Wong BA, Buccellato MA, Costa ER, Gross EA, et al. (2000) Direct olfactory transport of inhaled manganese ((54)MnCl(2)) to the rat brain: toxicokinetic investigations in a unilateral nasal occlusion model. Toxicol Appl Pharmacol 169: 238-248.
  169. Sen S, Flynn MR, Du G, Tröster AI, An H, et al. (2011) Manganese accumulation in the olfactory bulbs and other brain regions of "asymptomatic" welders. Toxicol Sci 121: 160-167.
  170. Thompson K, Molina RM, Donaghey T, Schwob JE, Brain JD, et al. (2007) Olfactory uptake of manganese requires DMT1 and is enhanced by anemia. FASEB J 21: 223-230.
  171. Knöpfel M, Zhao L, Garrick MD (2005) Transport of divalent transition-metal ions is lost in small-intestinal tissue of b/b Belgrade rats. Biochemistry 44: 3454-3465.
  172. Au C, Benedetto A, Aschner M (2008) Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 29: 569-576.
  173. Aisen P, Aasa R, Redfield AG (1969) The chromium, manganese, and cobalt complexes of transferrin. J Biol Chem 244: 4628-4633.
  174. Attieh ZK, Mukhopadhyay CK, Seshadri V, Tripoulas NA, Fox PL (1999) Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 274: 1116-1123.
  175. Jursa T, Smith DR (2009) Ceruloplasmin alters the tissue disposition and neurotoxicity of manganese, but not its loading onto transferrin. Toxicol Sci 107: 182-193.
  176. He L, Girijashanker K, Dalton TP, Reed J, Li H, et al. (2006) ZIP8, member of the solute-carrier-39 (SLC39) metal-transporter family: characterization of transporter properties. Mol Pharmacol 70: 171-180.
  177. Ingersoll RT, Montgomery EB Jr, Aposhian HV (1995) Central nervous system toxicity of manganese. I. Inhibition of spontaneous motor activity in rats after intrathecal administration of manganese chloride. Fundam Appl Toxicol 27: 106-113.
  178. Schmitt C, Strazielle N, Richaud P, Bouron A, Ghersi-Egea JF (2011) Active transport at the blood-CSF barrier contributes to manganese influx into the brain. J Neurochem 117: 747-756.
  179. Erikson KM, Aschner M (2006) Increased manganese uptake by primary astrocyte cultures with altered iron status is mediated primarily by divalent metal transporter. Neurotoxicology 27: 125-130.
  180. Rosenstock HA, Simons DG, Meyer JS (1971) Chronic manganism. Neurologic and laboratory studies during treatment with levodopa. JAMA 217: 1354-1358.
  181. Hine CH, Pasi A (1975) Manganese intoxication. West J Med 123: 101-107.
  182. Klos KJ, Chandler M, Kumar N, Ahlskog JE, Josephs KA (2006) Neuropsychological profiles of manganese neurotoxicity. Eur J Neurol 13: 1139-1141.
  183. Banta RG, Markesbery WR (1977) Elevated manganese levels associated with dementia and extrapyramidal signs. Neurology 27: 213-216.
  184. Burkhard PR, Delavelle J, Du Pasquier R, Spahr L (2003) Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 60: 521-528.
  185. Klos KJ, Ahlskog JE, Josephs KA, Fealey RD, Cowl CT, et al. (2005) Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol 62: 1385-1390.
  186. Benedetto A, Au C, Aschner M (2009) Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease. Chem Rev 109: 4862-4884.
  187. Claus Henn B, Ettinger AS, Schwartz J, Téllez-Rojo MM, Lamadrid-Figueroa H, et al. (2010) Early postnatal blood manganese levels and children's neurodevelopment. Epidemiology 21: 433-439.
  188. Dörner K, Dziadzka S, Höhn A, Sievers E, Oldigs HD, et al. (1989) Longitudinal manganese and copper balances in young infants and preterm infants fed on breast-milk and adapted cow's milk formulas. Br J Nutr 61: 559-572.
  189. Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 41: 959-998.
  190. Winder BS (2010) Manganese in the air: are children at greater risk than adults? J Toxicol Environ Health A 73: 156-158.
  191. Versieck J, Barbier F, Speecke A, Hoste J (1974) Manganese, copper, and zinc concentrations in serum and packed blood cells during acute hepatitis, chronic hepatitis, and posthepatitic cirrhosis. Clin Chem. 20: 1141-1145.
  192. Layrargues GP, Rose C, Spahr L, Zayed J, Normandin L, et al. (1998) Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis 13: 311-317.
  193. Klos KJ, Ahlskog JE, Kumar N, Cambern S, Butz J, et al. (2006) Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology 67: 1984-1989.
  194. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, et al. (1996) Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 24: 1116-1120.
  195. Barron TF, Devenyi AG, Mamourian AC (1994) Symptomatic manganese neurotoxicity in a patient with chronic liver disease: correlation of clinical symptoms with MRI findings. Pediatr Neurol 10: 145-148.
  196. Butterworth RF, Spahr L, Fontaine S, Layrargues GP (1995) Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 10: 259-267.
  197. Ejima A, Imamura T, Nakamura S, Saito H, Matsumoto K, et al. (1992) Manganese intoxication during total parenteral nutrition. Lancet 339: 426.
  198. Fell JM, Reynolds AP, Meadows N, Khan K, Long SG, et al. (1996) Manganese toxicity in children receiving long-term parenteral nutrition. Lancet 347: 1218-1221.
  199. Dickerson RN (2001) Manganese intoxication and parenteral nutrition. Nutrition 17: 689-693.
  200. Wilson DC, Tubman TR, Halliday HL, McMaster D (1992) Plasma manganese levels in the very low birth weight infant are high in early life. Biol Neonate 61: 42-46.
  201. Kafritsa Y, Fell J, Long S, Bynevelt M, Taylor W, et al. (1998) Long-term outcome of brain manganese deposition in patients on home parenteral nutrition. Arch Dis Child 79: 263-265.
  202. Gavin CE, Gunter KK, Gunter TE (1992) Mn2+ sequestration by mitochondria and inhibition of oxidative phosphorylation. Toxicol Appl Pharmacol 115: 1-5.
  203. Gavin CE, Gunter KK, Gunter TE (1990) Manganese and calcium efflux kinetics in brain mitochondria. Relevance to manganese toxicity. Biochem J 266: 329-334.
  204. Chen JY, Tsao GC, Zhao Q, Zheng W (2001) Differential cytotoxicity of Mn(II) and Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol 175: 160-168.
  205. Gunter TE, Gerstner B, Lester T, Wojtovich AP, Malecki J, et al. (2010) An analysis of the effects of Mn2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol 249: 65-75.
  206. Milatovic D, Zaja-Milatovic S, Gupta RC, Yu Y, Aschner M (2009) Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol 240: 219-225.
  207. Milatovic D, Yin Z, Gupta RC, Sidoryk M, Albrecht J, et al. (2007) Manganese induces oxidative impairment in cultured rat astrocytes. Toxicol Sci 98: 198-205.
  208. Gunter TE, Gavin CE, Aschner M, Gunter KK (2006) Speciation of manganese in cells and mitochondria: a search for the proximal cause of manganese neurotoxicity. Neurotoxicology 27: 765-776.
  209. Paris I, Segura-Aguilar J (2011) The role of metal ions in dopaminergic neuron degernation in Parkinsonism and Parkinson's disease. Monatsh Chem 142: 365-374.
  210. Marreilha dos Santos AP, Santos D, Au C, Milatovic D, Aschner M, et al. (2008) Antioxidants prevent the cytotoxicity of manganese in RBE4 cells. Brain Res 1236: 200-205.
  211. Benedetto A, Au C, Avila DS, Milatovic D, Aschner M (2010) Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in Caenorhabditis elegans. PLoS Genet 6: pii-e1001084.
  212. Stredrick DL, Stokes AH, Worst TJ, Freeman WM, Johnson EA, et al. (2004) Manganese-induced cytotoxicity in dopamine-producing cells. Neurotoxicology 25: 543-553.
  213. Zhao F, Cai T, Liu M, Zheng G, Luo W, et al. (2009) Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. Toxicol Sci 107: 156-164.
  214. Kern CH, Smith DR (2011) Preweaning Mn exposure leads to prolonged astrocyte activation and lasting effects on the dopaminergic system in adult male rats. Synapse 65: 532-544.
  215. Burton NC, Guilarte TR (2009) Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. Environ Health Perspect 117: 325-332.
  216. Burton NC, Schneider JS, Syversen T, Guilarte TR (2009) Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. Toxicol Sci 111: 131-139.
  217. Reaney SH, Kwik-Uribe CL, Smith DR (2002) Manganese oxidation state and its implications for toxicity. Chem Res Toxicol 15: 1119-1126.
  218. Reaney SH, Smith DR (2005) Manganese oxidation state mediates toxicity in PC12 cells. Toxicol Appl Pharmacol 205: 271-281.
  219. Suarez N, Walum E, Eriksson H (1995) Cellular neurotoxicity of trivalent manganese bound to transferrin or pyrophosphate studied in human neuroblastoma (SH-SY5Y) cell cultures. Toxicol In Vitro 9: 717-721.
  220. Archibald FS, Tyree C (1987) Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophys 256: 638-650.
  221. Reaney SH, Bench G, Smith DR (2006) Brain accumulation and toxicity of Mn(II) and Mn(III) exposures. Toxicol Sci 93: 114-124.
  222. Bock NA, Paiva FF, Nascimento GC, Newman JD, Silva AC (2008) Cerebrospinal fluid to brain transport of manganese in a non-human primate revealed by MRI. Brain Res 1198: 160-170.
  223. Aschner M, Erikson KM, Dorman DC (2005) Manganese dosimetry: species differences and implications for neurotoxicity. Crit Rev Toxicol 35: 1-32.
  224. Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, et al. (2008) Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 107: 1236-1247.
  225. Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, et al. (2006) Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 202: 381-390.
  226. Anderson JG, Cooney PT, Erikson KM (2007) Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol 23: 179-184.
  227. Ingersoll RT, Montgomery EB Jr, Aposhian HV (1999) Central nervous system toxicity of manganese. II: Cocaine or reserpine inhibit manganese concentration in the rat brain. Neurotoxicology 20: 467-476.
  228. Chen MK, Lee JS, McGlothan JL, Furukawa E, Adams RJ, et al. (2006) Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. Neurotoxicology 27: 229-236.
  229. Criswell SR, Perlmutter JS, Videen TO, Moerlein SM, Flores HP et al. (2011) Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology 76: 1296-1301.
  230. Kern CH, Stanwood GD, Smith DR (2010) Preweaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levels. Synapse 64: 363-378.
  231. Golub MS, Hogrefe CE, Germann SL, Tran TT, Beard JL, et al. (2005) Neurobehavioral evaluation of rhesus monkey infants fed cow's milk formula, soy formula, or soy formula with added manganese. Neurotoxicol Teratol 27: 615-627.
  232. Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S (2010) Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70: 271-288.
  233. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasić JR, et al. (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 105: 78-90.
  234. Connors SL, Levitt P, Matthews SG, Slotkin TA, Johnston MV, et al. (2008) Fetal mechanisms in neurodevelopmental disorders. Pediatr Neurol 38: 163-176.
  235. Rodier PM (1995) Developing brain as a target of toxicity. Environ Health Perspect 103 Suppl 6: 73-76.
  236. Rice D, Barone S Jr (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108 Suppl 3: 511-533.
  237. Fitzsimonds RM, Poo MM (1998) Retrograde signaling in the development and modification of synapses. Physiol Rev 78: 143-170.
  238. van Wijngaarden E, Campbell JR, Cory-Slechta DA (2009) Bone lead levels are associated with measures of memory impairment in older adults. Neurotoxicology 30: 572-580.
  239. Landrigan PJ (2010) What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 22: 219-225.
  240. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, et al. (2005) Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 113: 1230-1233.
  241. Williams BB, Kwakye GF, Wegrzynowicz M, Li D, Aschner M, et al. (2010) Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system. Toxicol Sci 117: 169-179.
  242. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41: 308-315.
  243. Bouchard M, Laforest F, Vandelac L, Bellinger D, Mergler D (2007) Hair manganese and hyperactive behaviors: pilot study of school-age children exposed through tap water. Environ Health Perspect 115: 122-127.
  244. Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93: 23-58.
  245. WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf accessed 8/30/2011
  246. Suk WA, Ruchirawat KM, Balakrishnan K, Berger M, Carpenter D, et al. (2003) Environmental threats to children's health in Southeast Asia and the Western Pacific. Environ Health Perspect 111: 1340-1347.
  247. Shah F, Kazi TG, Afridi HI, Baig JA, Khan S, et al. (2010) Environmental exposure of lead and iron deficit anemia in children age ranged 1-5 years: a cross sectional study. Sci Total Environ 408: 5325-5330.
  248. Del Razo LM, Arellano MA, Cebrián ME (1990) The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico. Environ Pollut 64: 143-153.
  249. Tareq SM, Safiullah S, Anawar HM, Rahman MM, Ishizuka T (2003) Arsenic pollution in groundwater: a self-organizing complex geochemical process in the deltaic sedimentary environment, Bangladesh. Sci Total Environ 313: 213-226.
  250. Anawar HM, Akai J, Mostofa KM, Safiullah S, Tareq SM (2002) Arsenic poisoning in groundwater: health risk and geochemical sources in Bangladesh. Environ Int 27: 597-604.
  251. Smith AH, Lingas EO, Rahman M (2000) Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ 78: 1093-1103.
  252. Calderón J, Navarro ME, Jimenez-Capdeville ME, Santos-Diaz MA, Golden A, et al. (2001) Exposure to arsenic and lead and neuropsychological development in Mexican children. Environ Res 85: 69-76.
Citation: Neal AP, Guilarte TR (2012) Mechanisms of Heavy Metal Neurotoxicity: Lead and Manganese. J Drug Metab Toxicol S5:002.

Copyright: © 2012 Neal AP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top